NC- Scan, a diagnostic technique for detecting and targeting necrosis
The targeting of necrosis in the living human body will offer many medical solutions. One of the most promising solutions is the as yet unmet medical need of visualizing and proving the efficacy of chemotherapy in solid tumor cancer treatment.
Responsible for an estimated 9.6 million deaths in 2018, cancer is one of the leading causes of death in the world. The incidence is expected to reach 15 million in 2020. Tackling necrosis provides crucial medical solutions and a significantly better quality of care for millions of people with cancer.
Coretag has therefore chosen to use their platform technology to address a major unmet medical need in healthcare. The NC-Scan can greatly improve chemotherapy in the treatment of solid tumors by visualizing cell death as a result of chemotherapy. This will permit identifying identify early responders (35%) and non-responders (65%) to treatment.
Results after 24 to 36 hours
In patients with solid tumors, the NC-Scan can inform within 24 to 36 hours after the (first) administration whether the therapy is effective. If found to be ineffective, it can then be stopped immediately instead of 5 to 9 months later after many more administrations. Potentially effective second or third line therapies may then be started and tested on the short term.
Most cancer therapies have many adverse side-effects, vary widely in efficacy (average 33%) and are very expensive (immunotherapy up to $250,000 per treatment). Use of the NC-Scan will do away with the risk of unnecessary side-effects, exert a potential life-saving effect and a huge cost-saving potential.